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Abstract Nephroblastoma prognosis has dramatically
improved, but an unfavourable prognostic subgroup
warrants development of novel therapeutic strategies.
Selective KIT, PDGFRα and epidermal growth factor
receptor (EGFR) tyrosine kinase inhibition evolved as
powerful targeted therapy for gastrointestinal stromal
tumours and non-small-cell lung cancer. To investigate a
potential role for tyrosine kinase inhibition, we analyzed
209 nephroblastomas for immunohistochemical KIT and
EGFR expression, 63 nephroblastomas for mutations in
KIT exons 9, 11, 13, EGFR exons 18, 19, 20 and 21, and
all 209 nephroblastomas for PDGFRα exons 12, 14 and
18. Twenty-two tumours (10.5%) expressed KIT, 31
(14.8%) EGFR, and 10 (4.8%) both KIT and EGFR,
respectively. KIT expression was relatively more common
among high-risk tumours (6/27; 22.3%) compared to low-/
intermediate-risk tumours (26/181; 14.4%). Nine patients
deceased, four of which had high-risk tumours with KIT
expression in two of four and EGFR expression in one of
four. There were no KIT, PDGFRα or EGFR mutations.
Our results suggest no significant contribution of KIT,
EGFR or PDGFRα mutations to nephroblastoma patho-
genesis. Despite a trend towards association of immuno-
histochemical KIT and EGFR expression with poor
outcome in high-risk nephroblastomas, statistical analysis
did not yield significant correlations in this subgroup.
Therefore, it remains open if KIT, PDGFRα or EGFR
tyrosine kinase inhibition constitute a therapeutic target in
nephroblastoma in the absence of KIT, PDGFRα or EGFR
mutations.
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Introduction
Nephroblastoma is the most common malignant renal tumour
in childhood and affects 1 in 8,000 children [11]. Over the past
three decades, multimodal nephroblastoma therapy has been a
story of success. Nephroblastoma prognosis has improved
dramatically, and overall 10-year survival now approaches
85% [15]. Nevertheless, a poor prognostic subgroup of
nephroblastomas remains. Diffuse anaplasia, persistent blaste-
ma after chemotherapy, allelic loss at 1p or 16q, TP53
mutations and advanced tumour stage have been identified as
adverse prognostic factors [3, 10, 11, 31, 32]. Therefore,
development of novel therapeutic strategies is mandatory.
Over recent years, receptor tyrosine kinases have
evolved as focus of research for potential targeted tumour
therapy [26]. Transmembrane receptor tyrosine kinases play
an important role in the modulation of growth factor
signalling [33]. Receptor tyrosine kinases KIT (v-kit
Hardy-Zuckermann 4 feline sarcoma viral oncogene homo-
logue), PDGFRα (platelet-derived growth factor receptor
α) and EGFR (epidermal growth factor receptor) participate
in cell growth and are implicated in malignant transforma-
tion and tumour progression. KIT is claimed to play an
important role in kidney organogenesis. It is expressed
during metanephrogenesis in blastema and immature
epithelium and in the mature kidney in proximal and distal
tubules [27]. KIT expression has been demonstrated in a
subset of renal cell carcinomas, oncocytomas, mesoblastic
nephromas, angiomyolipomas and a small series of neph-
roblastomas [22, 30]. The KIT internal tyrosine kinase
component is structurally related to the platelet-derived
growth factor receptor α [40]. PDGFRα overexpression has
been described in carcinomas of colon, breast, lung, ovary
and pancreas. Expression of activated PDGFRα in stromal
cells of colon carcinomas has been associated with
metastatic potential [23]. EGFR is expressed in most
human tissues and plays an important role in normal cell
biology. In the kidney, the human epidermal growth factor
family members play a significant role in the mesenchymal
to epithelial transition during renal tubulogenesis [41].
EGFR expression is found in a number of tumours,
particularly squamous cell carcinomas, sarcomas, gliomas,
breast, bladder and lung tumours. In nephroblastoma,
EGFR expression has been described in a subset of tumours
in one small series [14].
Selective inhibition of receptor tyrosine kinases has
evolved as a powerful, targeted therapeutic tool in a number
of tumours, and the spectrum of small molecule receptor
tyrosine kinase inhibitors is rapidly expanding [26].
Imatinib/Gleevec® and Gefitinib/Iressa® are now well
established as therapeutic inhibitors of KIT and EGFR,
respectively. In particular, gastrointestinal stromal tumours
and leukemias have been shown to be amenable to receptor
tyrosine kinase inhibitor therapy [16, 17, 21, 34]. KIT
iuxtamembranous exon 9, 11 and 13 mutations correspond
with susceptibility to tyrosine kinase inhibition and im-
proved survival in gastrointestinal stromal tumours and
myeloic leukemia [8, 9, 13, 36, 38]. Up to 90% of
gastrointestinal stromal tumours are KIT-mutated, and exon
11 mutations are most common [20, 25]. Approximately 7–
12% of gastrointestinal stromal tumours without KIT
mutations show PDGFRα mutations instead and are
susceptible, though to a lesser degree, to imatinib treatment
[7, 20, 38]. Interestingly, KIT and PDGFRα are located in
the same chromosomal region 4q12 [35]. PDGFRα
mutations are most often located in exon 18, and rarely in
exons 12 and 14. In clinical phase 3 studies, a new generation
of KIT/PDGFR receptor tyrosine kinase inhibitors for
resistant tumours, e.g. sunitinib/Sutent®, are currently being
tested [6]. Furthermore, activating EGFR gene mutations of
exons 18, 19, 20 or 21 in non-small-cell lung carcinoma
result in inhibition of apoptosis, in tumour proliferation,
angiogenesis, invasion and metastasis [29, 33]. EGFR gene
mutations confer susceptibility to gefitinib/Iressa® EGFR
receptor tyrosine kinase inhibition [19].
In nephroblastomas, immunohistochemical KIT and
EGFR expression has only been investigated in a small
number of tumours [14], and neither KIT, PDGFRα nor
EGFR mutations have been reported in these tumours so
far. In a separate small set of 12 KIT-positive nephroblas-
tomas, we detected mutations of KIT exon 11 in two
tumours (Bruder et al., manuscript submitted). Moreover,
no information is available so far with regard to tyrosine
kinase expression and outcome. To provide a rationale for
potential targeted small molecule receptor tyrosine kinase
inhibition in nephroblastomas, we screened 209 nephro-
blastomas for immunohistochemical KIT and EGFR
expression. Tumours with KIT expression were analysed
for mutations of KIT exons 9, 11, 13. Similarly, tumours
with EGFR expression were submitted to sequence analysis
of EGFR exons 18, 19, 20 and 21. All 209 tumours were
analysed for PDGFRα exons 12, 14 and 18 mutations.
Materials and methods
Nephroblastomas
From the archives of the Kiel Paediatric Tumour Registry,
209 nephroblastomas were compiled (1993–2002). Patient
data were available on gender, age and stage at diagnosis,
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tumour subtype, therapy mode and patient outcome. Male
to female ratio was 1:1.27. Median patient age was
4.3 years. Preoperative chemotherapy had been adminis-
tered to 181 patients according to the current International
Paediatric Oncology Society (SIOP) protocol, and 28
patients underwent primary tumour resection. All nephro-
blastomas were classified according to the current SIOP
classification [39] (Fig. 1). This current nephroblastoma
classification accounts for the differential prognostic impact
of blastema before and after chemotherapy and newly
categorises residual blastema after chemotherapy in
tumours with more than one third viable tumour tissue
and more than two thirds of the viable tumour tissue of
blastemal type (i.e. blastema predominant) as high-risk
histology [39]. Tumours were reviewed by IL, DH, EB and
SCW as well as by the SIOP nephroblastoma panel.
For tumour diagnosis, at least one block per centimeter
tumour diameter was embedded. A mean of five blocks
were available for tumour classification at the Kiel
Paediatric Tumour Registry.
A paraffin tumour tissue microarray was constructed for
efficient expression screening as previously described [24]
(Fig. 2). For adult tumours, like urothelial carcinoma, one
single punch cylinder per tumour was previously shown to
be representative of each tumour [28]. For the present study
of nephroblastoma, the paraffin tissue microarray construc-
tion technique was modified and specifically adapted to
account for nephroblastoma as a heterogeneous embryonal
tumour. Therefore, each histological tumour component of
all 209 nephroblastomas was sampled, the respective
tumour area circled on an H&E slide, and the corre-
sponding paraffin block area marked before punching,
resulting in five to six punch cylinders (mean 5.4, median
5) for each tumour on a total of three recipient blocks with
a total of 1,178 punch cylinders. Normal renal parenchyma
was included whenever present.
Fig. 1 Conventional histology: a Blastemal nephroblastoma (H&E×200). b Epithelial nephroblastoma (H&E×200). c Stromal nephroblastoma
(H&E×200). d Diffuse anaplastic nephroblastoma (H&E×200)
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Criteria for tumour components for inclusion in the
paraffin tissue microarray comprised all known histological
nephroblastoma components, i.e. blastemal, epithelial,
stromal and anaplastic tumour areas [11]. To carefully
account for tumour heterogeneity and regional tumour
variability, each histological tumour component was dili-
gently selected for punching and was represented on the
paraffin tissue microarray. Tumour punch samples originat-
ed from one or multiple blocks (median 3 blocks, mean 2.7
blocks). Punch core needle diameter was 0.6 mm as
described previously [24, 28].
Immunohistochemistry
Paraffin tissue microarray sections were cut at 4 μm
according to a protocol standardised in our laboratory.
Immunohistochemistry for KIT receptor CD117 protein
was performed on a Bond™ Immunostainer (Bond Max,
Vision BioSystems; Figs. 3 and 4). For KIT/ CD117
immunohistochemistry, sections were pretreated in the
manufacturer’s ‘ Epitope Retrieval buffer 2’ (Tris–EDTA
buffer at pH 8.8) for 20 min at 100°C, incubated with
polyclonal antibody Anti CD117 primary antibody (DAKO,
1:1000), followed by Bond polymer refine detection kit
according to the manufacturer’s protocol. A gastrointestinal
tumour served as positive control. As it is known that KIT
immunohistochemistry is prone to false positive staining
results [20], the immunohistochemical reaction for KIT was
carefully tested and set up in our laboratory with particular
attention to negative controls so as to avoid false positive
immunohistochemical staining results. For EGFR, immuno-
histochemistry was performed according to the EGFR
pharmDx™, Code K1492 (Dako Cytomation) kit protocol.
A cytospin of an EGFR-positive cell line contained in the
kit served as positive control. A test array slide, containing
a combination of normal and neoplastic human tissue cores,
was included as negative control for each KIT and EGFR
immunohistochemical reaction. Immunohistochemistry for
PDGFRα was not performed because in our experience,
PDGFRα immunohistochemistry is currently not reliable.
Instead, all tumours were submitted to PDGFRα sequence
analysis (see below).
Immunohistochemical staining for KIT/CD117 and
EGFR was evaluated for each individual array punch tissue
sample and recorded according to tumour tissue component
and intensity of staining. Staining intensity was graded
from + to +++, with + denoting faint cytoplasmatic
staining, ++ intermediate cytoplasmatic staining and +++
exclusively only awarded to those tumours with distinct
membranous in addition to cytoplasmic staining (Table 1).
Immunohistochemical scoring was performed by SCW and
EB independent of further tumour and patient information.
Tumours were classified as KIT- or EGFR-positive,
respectively, only in the presence of membranous KIT or
EGFR expression and selected for subsequent DNA
sequence analysis. Immunohistochemical scoring was
amended to include the percentage of KIT- or EGFR-
positive cells. In Table 1, the percentage of immuno-
histochemically positive tumour cells is provided.
KIT, PDGFRα and EGFR sequence analysis
For KIT, PDGFRα and EGFR sequence analysis, those
tumours with strong immunohistochemical KIT and/or
EGFR expression were selected. As in gastrointestinal
Fig. 2 Nephroblastoma array: a–c Overview of one paraffin block of
the constructed nephroblastoma array (a H&E, b CD117/ KIT
immunohistochemistry, c EGFR immunohistochemistry slide scans)
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stromal tumours the presence of either KIT or PDGFRα
mutations is regarded as predictive of tumour response to
receptor tyrosine kinase inhibition [2], we proceeded to
submit all KIT expressing nephroblastomas not only to KIT
but also to PDGFRα sequence analysis. KIT and PDGFRα
sequence analysis was performed on 22 of 209 tumours
with strong +++ membranous and cytoplasmic CD117
expression. EGFR sequencing was performed on 31 of 209
tumours with strong +++ membranous and cytoplasmic
EGFR expression. Ten nephroblastomas revealed both
EGFR and KIT expression and were submitted to KIT,
PDGFRα as well as EGFR sequencing analysis. Con-
sequently, KIT and EGFR DNA sequence analysis was
performed on a total of 63 nephroblastomas. In addition, in
the absence of an immunohistochemical PDGFRα screen-
ing test, all 177 CD117 negative nephroblastomas were
submitted to PDGFRα sequence analysis, resulting in
PDGFRα sequence analysis of all 209 nephroblastomas
included in this study.
For DNA extraction, one to three punch cylinders
0.6 mm in diameter were removed from identical matched
tumour regions of the original paraffin tissue blocks of each
selected nephroblastoma. DNA was extracted according to
the SIOP 1 and the QIAamp® DNA mini kit DNA extrac-
tion protocols (Qiagen AG, Basel, Switzerland) [37]. The
extracted DNA was submitted to a semi-nested or nested
multiplex polymerase chain reaction (PCR) for KIT exons
9, 11, 13, PDGFRα exons 12, 14 and 18 and EGFR exons
Fig. 3 KIT immunohistochemistry: a Membranous KIT expression in
a blastemal nephroblastoma (KIT immunohistochemistry×630). b
Focal membranous KIT expression in a nephroblastoma with diffuse
anaplasia (KIT immunohistochemistry×630). c, d Focal membranous
KIT expression in a nephroblastoma of mixed subtype (KIT
immunohistochemistry×630). c Represents a blastemal component
of this tumour, whereas d depicts a focus of KIT expression in
immature epithelium in addition to a group of blastemal cells (KIT
immunohistochemistry×630)
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18, 19, 20 and 21. DNA sequencing was performed on the
PCR products on an ABI PRISM 310xl Genetic Analyzer
(Applied BioSystems). Sequencing primers were identical
to initial PCR primers. Primer sequences are given in
Table 2.
Statistical analysis
For statistical analysis, associations between follow-up
data, histological nephroblastoma subtype and immuno-
histochemical expression of KIT and EGFR were analysed,
respectively. The association between survival, recurrence
and metastasis with KIT and EGFR expression was
evaluated using the chi-square test or Fisher’s exact test.
P values<0.05 were considered statistically significant. All
analyses were carried out using SAS (version 9.0, The SAS
Institute, NC, USA).
Results
In this study, we analyzed 209 nephroblastomas for
immunohistochemical KIT and EGFR expression, a total
of 63 tumours for mutations in KIT exons 9, 11, 13, EGFR
exons 18, 19, 20 and 21, as well as PDGFRα exons 12, 14
and 18 in the total series of 209 nephroblastomas. Tumour
localisation was equally distributed between both kidneys,
with 108 tumours localised in the right and 101 in the left
kidney.
Fig. 4 EGFR immunohistochemistry: a Membranous EGFR expres-
sion in a blastemal predominant nephroblastoma. At the top border of
the figure is an EGFR-negative tubule (EGFR immunohistochemis-
try×630). b Membranous EGFR expression in a focus of squamous
epithelium. Surrounding stroma is negative for EGFR (EGFR
immunohistochemistry×630). c EGFR expression in a stromal
predominant nephroblastoma. Foci of rhabdomyoblastic differentia-
tion are negative for EGFR (EGFR immunohistochemistry×630). d
EGFR expression in blastemal foci and immature epithelium in a
mixed type nephroblastoma (EGFR immunohistochemistry×630)
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The 209 tumours were classified according to the SIOP
classification (Table 1, Fig. 1): two low-risk tumours (1%;
CPDN: cystic partially differentiated nephroblastoma), 179
intermediate-risk tumours (86%), 27 high-risk tumours
(12.5%) and one non-classifiable tumour (0.5%). Tumour
group details are provided in Table 1. The 179 nephro-
blastomas of intermediate risk were: 91 mixed (52%), 42
regressive (23%), 29 stromal (16%), nine pre-chemotherapy
blastemal (5%), six epithelial (3%) and two with focal
anaplasia (1%). The 27 nephroblastomas of high-risk
histology were: 21 of 27 (78%) post-chemotherapy blaste-
mal and 6 of 27 diffuse anaplastic nephroblastomas (22.3%).
The nephroblastomas classified as post-chemotherapy blas-
temal showed more than one third viable tissue of which
more than two thirds of the viable tumour tissue was of
blastemal type (i.e. blastema predominant).
Follow-up between 7 and 132 months (mean 66 months)
was available for all 209 patients. Of 209 patients, nine
(4%) died of tumour: five intermediate-risk tumours (56%;
three regressive and two mixed), four high-risk tumours
(44%; three post-chemotherapy blastemal, one diffuse
anaplastic nephroblastoma; Fig. 1). Of the 27 patients with
a high-risk histology tumour, four died (14.8%). Thus, our
study confirms the association of high-risk nephroblasto-
mas with poor outcome. Of the nine patients deceased, four
had metastases, predominantly pulmonary: two patients
with intermediate-risk tumours (regressive) and two high-
risk tumours (one post-chemotherapy blastemal, one diffuse
anaplastic nephroblastoma). A total of 27 (13%) tumours
metastasised: 24 intermediate-risk tumours [89%; ten mixed
(37%), two stromal (7%), ten regressive (37%; two patients
died], one epithelial (4%), one pre-chemotherapy blastemal
nephroblastoma (4%) and three high-risk tumours (11%;
two post-chemotherapy blastemal (7%; one patient died),
one with diffuse anaplasia (4%; this patient died).
Immunohistochemistry for KIT and EGFR
Tumours with membranous immunohistochemical KIT or
EGFR expression were graded +++ and classified as
positive. Immunohistochemical results are provided in
Table 1. In most tumours, KIT and EGFR expression was
focal and observed in blastemal and immature epithelial
tumour components (Figs. 3 and 4). For more precise
analysis, the percentage of KIT- and EGFR-expressing
tumour cells per punch was estimated and is indicated in
Table 1. Assuming that each KIT- or EGFR-expressing
tumour area might be of potential biological relevance, all
tumours with membranous immunohistochemical KIT or
EGFR expression were classified as positive irrespective of
the percentage of positive tumour cells. Sixty-three (30.1%)
nephroblastomas demonstrated expression of KIT, EGFR or
both: 22 (10.6%) nephroblastomas were KIT-positive, 31
(14.8%) nephroblastomas were EGFR-positive, and 10
(4.8%) tumours expressed both KIT and EGFR. Conse-
quently, a total of 32 of 209 nephroblastomas (15.3%)
showed immunohistochemical KIT expression. Of these, 26
were intermediate-risk tumours (81.3%) and one was not
classifiable (3.1%). KIT expression was observed in 12
(37.5%) mixed nephroblastomas, seven (21.9%) stromal,
four (12.5%) regressive and three (9.4%) pre-chemotherapy
blastemal nephroblastomas. Of the 27 high-risk histology
Table 1 Clinicopathologic characteristics and immunohistochemistry (N=209): risk group, nephroblastoma subtype, membranous KIT and
EGFR expression, preoperative chemotherapy, adverse events, follow-up interval
Risk group Histology KIT expression EGFR
expression
KIT and EGFR
expression
Local
recurrence
Metastasis Death of
disease
Low 2 (1%) CPDN 2 (100%) 0 0 0 0 0 0
Intermediate 179 (86%) Blastemal (pretreatment) 9 (5%) 2 0 1 0 1 0
Epithelial 6 (3.4%) 0 0 0 1 1 0
Stromal 29 (16.2%) 7 7 2 1 2 0
Mixed 91 (50.8%) 12 23 4 6 10 2
Regressive 42 (23.5%) 4 7 2 3 10 3
Focal anaplasia 2 (1.1%) 0 0 0 0 0 0
High 27 (12.5%)
Blastemal (post-treatment)
21 (77.8%)
4 2 1 4 2 3
Diffuse anaplasia 6 (22.2%) 1 1 0 1 1 1
Unclassified (0.5%) Unclassified 1 (0.5%) 1 0 0 0 0 0
Total 209 (100%) 22 (10.6%) 31 (14.8%) 10 (4.8%) 16 (7.6%) 27 (12.9%) 9 (4.3%)
CPDN cystic partially differentiated nephroblastoma
Virchows Arch (2008) 452:637–650 643
nephroblastomas, six showed KIT expression (22.3%). Five
of 21 post-chemotherapy blastemal nephroblastomas and
one of six with diffuse anaplasia were KIT-positive. None
of the six epithelial, focal anaplastic or cystic partially
differentiated nephroblastomas showed KIT expression.
EGFR expression was observed in 41 of 209 nephroblas-
tomas (19.6%). Thirty-eight of them were intermediate-risk
tumours (92.7%) and three high-risk tumours (7.3%).
Similar to KIT, EGFR expression was observed predomi-
nantly in mixed nephroblastomas: 23 of 41 tumours
(56.1%) were mixed, seven (17.1%) were stromal, seven
(17.1%) regressive and one (2.4%) non-pretreated blastemal
nephroblastomas. Only 3 of 27 high-risk nephroblastomas
expressed EGFR, two (of 21) post-chemotherapy blastemal
and one (of 6) nephroblastoma with diffuse anaplasia. None
of the six epithelial, focal anaplastic or cystic partially
differentiated nephroblastomas showed EGFR expression.
Immunohistochemical scoring was amended to include
the percentage of KIT- or EGFR-positive cells in immuno-
histochemically positive tumour punches. In ESM Table 1,
the percentage of immunohistochemically positive tumour
cells per positive tumour punch is provided.
KIT exon 9, 11, 13, EGFR exon 18, 19, 20, 21, PDGFRα
exon 12, 14 and 18 sequence analysis
Sequence analysis for KIT and EGFR was performed on a
total of 63 tumours and for PDGFRα on all 209 tumours
from 209 patients. A total of 957 exons were sequenced.
Twenty-two nephroblastomas with KIT expression were
Table 2 Polymerase chain
reaction primer sequences Primer name Primer direction Primer sequence 5′→3′
KIT exon 9 Forward_1 TCC TAG AGT AAG CCA GGG CTT
Forward_2 (nested) AGC CAG GGC TTT TGT TTT CT
Reverse TGG TAG ACA GAG CCT AAA CAT CC
KIT exon 11 Forward CCA GAG TGC TCT AAT GAC TG
Reverse_1 AGC CCC TGT TTC ATA CTG AC
Reverse_2 (nested) ACT CAG CCT GTT TCT GGG AAA CTC
KIT exon 13 Forward_1 GCT TGA CAT CAG TTT GCC AG
Forward_2 (nested) TGA CAT CAG TTT GCC AGT TG
Reverse AAA GGC AGC TTG GAC ACG GCT TTA
PDGFRα exon 12 Forward_1 GCT CTG GTG CAC TGG GAC TTT GGT A
Forward_2nested TGG TGC ACT GGG ACT TTG GTA ATT CA
Reverse_1 TTG TGT GCA AGG GAA AAG GGA GTC TT
Reverse_2nested GGG AAA AGG GAG TCT TGG GAG GTT AC
PDGFRα exon 14 Forward_1 CTTTCAACAGCCACGGCCAGATC
Forward_2nested GGGGATGGAGAGTGGAGGATTTAAGC
Reverse_1 CAACAGCCACGGCCAGATCCAG
Reverse_2nested CAACCACATGTGTCCAGTGAAAATCCTC
PDGFRα exon 18 Forward_1 CAG CCA GTC TTG CAG GGG TGA TG
Forward_2nested GAT GGC TTG ATC CTG AGT CAT TTC TTC C
Reverse_1 GGG AGG ATG AGC CTG TCC AGT GTG
Reverse_2nested GAG CCT GTC CAG TGT GGG AAG TGT G
EGFR exon 18 Forward GCA TGG TGA GGG CTG AGG TGA
Forward_nested ACC CTT GTC TCT GTG TTC TTG TCC C
Reverse CCC CAC CAG ACC ATG AGA GGC
Reverse_nested GCC CAG CCC AGA GGC CTG TG
EGFR exon 19 Forward TGC CAG TTA ACG TCT TCC TTC
Forward_seminested AAC GTC TTC CTT CTC TCT CTG
Reverse CCA CAC AGC AAA GCA GAA AC
EGFR exon 20 Forward CCA CCA TGC GAA GCC ACA CTG A
Forward_nested CCA TGC GAA GCC ACA CTG ACG T
Reverse TCC TTA TCT CCC CTC CCC GTA TCT C
Reverse_nested CCC CTC CCC GTA TCT CCC TTC C
EGFR exon 21 Forward AGC TTC TTC CCA TGA TGA TCT GTC C
Forward_nested TCC CAT GAT GAT CTG TCC CTC ACA
Reverse GGC AGC CTG GTC CCT GGT GTC
Reverse_nested CAG GAA AAT GCT GGC TGA CCT AAA G
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selected for KIT exon 9, 11, 13 and PDGFRα exon 12, 14
and 18 sequence analysis. All 22 tumours contained KIT
exon 9, 11, 13 and PDGFRα exon 12, 14 and 18 wild-type
sequences (Fig. 5). The 31 nephroblastomas with immuno-
histochemical staining for EGFR were selected for EGFR
exon 18, 19, 20 and 21 sequence analysis. All 31 tumours
contained EGFR exon 18, 19, 20 and 21 wild-type
sequences (Fig. 5). The ten tumours with both KIT and
EGFR expression were selected for KIT exon 9, 11, 13,
PDGFRα exon 12, 14, 18 and for EGFR exon 18, 19, 20
and 21 sequence analysis. All ten tumours contained wild-
type sequences of KIT exons 9, 11, 13, PDGFRα exons 12,
14, and 18 and for EGFR exons 18, 19, 20 and 21. In
addition, all 177 immunohistochemically KIT-negative
nephroblastomas were submitted to PDGFRα sequence
analysis. Similar to the KIT immunohistochemically posi-
tive tumours, the immunohistochemically KIT-negative
nephroblastomas contained PDGFRα exon 12, 14 and 18
wild-type sequences.
PDGFRα sequence analysis was performed in double
independently in two separate laboratories at the Institute of
Pathology at the University Hospital in Basel, Switzerland
Fig. 5 KIT, PDGFRα and EGFR sequencing results: a KIT wild-type sequence (32 nephroblastomas). b PDGFRα wild-type sequence (209
nephroblastomas). c EGFR wild-type sequence (41 nephroblastomas)
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and at the Institute for Clinical Chemistry and Laboratory
Medicine at the University of Regensburg, Regensburg,
Germany.
All sequencing reactions were repeated twice. Repeat
mutation analyses yielded identical results.
Statistical analysis
Correlation of tyrosine kinase receptor expression
and outcome
Metastases occurred in 30 patients (14.1%), tumour
recurrences were observed in 17 patients (8%), and nine
patients died (4.2%). Although we observed a trend for KIT
expression in high-risk histology tumours with adverse
events, statistically, KIT expression was not significantly
associated with outcome, neither in the whole group of
nephroblastomas (p=0.18) nor in the group of low- or
intermediate-risk histology tumours nor in high-risk histology
tumours (p=0.062). KIT expression was independent of
immunohistochemical EGFR expression. Similar to KIT,
EGFR expression did not correlate with adverse events for
the total group of nephroblastomas analysed (p=0.224).
Comparison of treated and untreated nephroblastomas
Preoperative chemotherapy had been administered to 181
patients according to the current SIOP protocol, and 28
patients underwent primary tumour resection without
preoperative chemotherapy (see Table 3). In the tumour
group with preoperative chemotherapy, there were 27 high-
risk histology nephroblastomas, 153 intermediate risk
histology nephroblastomas and one unclassified nephro-
blastoma. In the tumour group without preoperative
chemotherapy, there were two low-risk histology tumours
and 26 intermediate-risk histology tumours, but no high-
risk tumour. None of the high-risk histology tumours were
treated with primary resection; all of these had received
preoperative chemotherapy.
Comparing the immunohistochemical results of the
total group of 209 tumours with those tumours treated
preoperatively, there is no statistical difference between
the total group and the group treated with preoperative
chemotherapy.
Comparison of immunohistochemical expression among
the preoperatively treated versus the preoperatively untreated
group yields a tendency towards a higher percentage of
KIT-expressing tumours in the preoperatively untreated
group (p=0.069). Seven of 26 preoperatively untreated
nephroblastomas of intermediate-risk histology showed KIT
expression, corresponding to 27%, as opposed to 19 of 153
(12%) of intermediate-risk histology nephroblastomas with
preoperative chemotherapy. As for EGFR expression, the
trend is similar but to a lesser degree (p=0.443): Seven of
26 (27%) preoperatively untreated nephroblastomas of
intermediate-risk histology showed EGFR expression versus
31 of 153 (21%) preoperatively treated intermediate-risk
histology nephroblastomas.
However, the numbers of individual intermediate-risk
histology subgroups without preoperative chemotherapy are
small, and analysis of larger numbers is required to confirm
such a trend. Similarly, the tumour spectrum within the
preoperatively treated versus preoperatively untreated
tumour group is different and is therefore likely to
introduce a bias into the comparison of these two
nephroblastoma groups.
As for outcome analysis among the preoperatively
untreated tumours and comparison with the preoperatively
treated tumours, a similar bias is likely.
None of the adverse events occurred in these 28
preoperatively untreated tumours except one surviving
patient with metastases of a KIT- and EGFR-negative
tumour of the intermediate-risk histology group. No patient
in the preoperatively untreated group died. All other
Table 3 Comparison of
immunohistochemical results
in treated and untreated
tumours
N=209
Chemotherapy N Histology risk group N KIT expression EGFR expression
Yes 181
High 27 5 of 27 (19%) 3 of 27 (12%)
Intermediate 153 19 of 153 (12%) 31 of 153 (21%)
Unclassified 1 1 0
No 28
High 0 0 0
Intermediate 26 7 of 26 (27%) 7 of 26 (27%)
Low 2 0 0
Total yes and no 209
High 27 5 of 27 (19%) 3 of 27% (12%)
Intermediate 179 26 of 179 (15%) 38 of 179 (21%)
Low 2 0 0
Unclassified 1 1 0
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adverse events occurred in those patients with preoperative
chemotherapy. All patients who died were in the group with
preoperative chemotherapy.
Discussion
Enhanced understanding of genetic alterations in nephro-
blastoma and identification of key molecular markers is
expected to provide the foundation for novel targeted
therapies to address currently poor prognostic nephroblas-
toma subgroups. Transmembrane receptor tyrosine kinases
play a crucial role in growth factor signalling cascades. The
role of tyrosine kinases for tumour growth and angiogenesis
in nephroblastomas has been described in previous studies
[1, 12, 14, 41]. Constitutional protein kinase activation by
somatic mutation is a frequent mechanism of tumouri-
genesis [33]. Targeted small molecule drugs have emerged
as elegant and efficient anti-cancer strategies, and selective
receptor tyrosine kinase inhibition evolves as focus of
research for novel therapies. As receptor tyrosine kinases,
KIT and EGFR play a significant role in renal organo-
genesis and expression has previously been described in a
small series of nephroblastomas, we set out to determine
the prevalence of KIT and EGFR expression in a large
series of 209 nephroblastomas. So far, as known from the
experience in gastrointestinal stromal tumours, leukemias
and non-small-cell lung cancer, susceptibility to kinase
inhibition appears to be linked to constitutionally activating
gene mutations, which has held true for KIT as well as for
EGFR. Neither KIT nor EGFR mutations have been
described in nephroblastomas so far. In a separate small
set of 12 KIT-positive nephroblastomas, we detected
mutations of KIT exon 11 in two tumours (Bruder et al.,
manuscript submitted). Therefore, we also determined KIT
and EGFR gene sequences of most commonly involved
exons in 63 nephroblastomas and PDGFRα of all 209
nephroblastomas to investigate a rationale for potential
targeted tyrosine kinase inhibitor therapy in nephroblastoma.
Among the 209 nephroblastomas investigated in this
study, we found KIT and/or EGFR expression in 63
tumours. Interestingly, KIT expression was more frequent
among tumours of high-risk histology (6/27; 22.3%)
compared with those of low- and intermediate-risk (26/
181; 14.4%). In contrast, EGFR expression was less
frequent in high-risk nephroblastomas (3/27; 11%) than in
intermediate- and low-risk tumours (38/181; 20%). Did
KIT or EGFR expression confer a different prognosis in our
set of nephroblastomas? If nephroblastomas with adverse
events defined as local recurrence, metastasis or death from
disease were regarded separately, adverse events occurred
in 37 (17.7%) of the total series of 209 tumours and in five
(12.2%) of 41 tumours with EGFR expression. Conversely,
adverse events occurred in 32 (19%) of 168 tumours
without EGFR expression. Furthermore, adverse events
were recorded in three (9.4%) of 32 KIT-expressing
tumours, as opposed to adverse events in 34 (19.2%) of
177 KIT-negative tumours. In contrast, in 200 surviving
patients, KIT and EGFR were positive in 15% and 19.5%,
respectively. It therefore appears that KIT or EGFR
expression alone may be associated with slightly better
tumour outcome if regarded independently from tumour
histology. However, in nine patients who died of their
tumour, two (22.3%) tumours showed strong KIT expres-
sion and another 2 (22.3%) showed strong EGFR expres-
sion, while KIT and EGFR were positive in slightly lower
proportions in the 200 surviving patients, 15% and 19.5%,
respectively. Moreover, if evaluated in the context of
tumour histology, four of the nine patients who died of
disease had tumours of high-risk histology, and among
these four tumours, two strongly expressed KIT, and one
was EGFR-positive (p=0.371). Although these findings
suggest a tendency that KIT expression, and to a minor
degree also EGFR expression, may potentially be associated
with poor outcome in the context of unfavourable histology,
we were unable to statistically prove such a correlation. This
is also true for tumours of low- and intermediate-risk
histology associated with adverse events in relation to KIT
and EGFR expression: Of 182 tumours with low- and
intermediate-risk histology, only one (3.8%) of 26 KIT-
expressing tumours and four (10.5%) of 38 EGFR express-
ing tumours (p=0.206) were associated with adverse events,
whereas, conversely, 31 of 156 (19.9%) KIT-negative and 28
of 144 (19.4%) EGFR-negative tumours were associated
with adverse events. Even if these results might suggest a
tendency that low- and intermediate-risk histology nephro-
blastomas with KIT and EGFR expression appear to be
associated with a better prognosis, this correlation is
statistically not significant. As numbers of subgroups are
small, this issue requires to be addressed in a still larger
study. Nevertheless, these results suggest that KIT and
EGFR expression should be evaluated in the context of
tumour histology and outcome. The potential correlation of
KIT and EGFR expression with better prognosis in low-/
intermediate-risk histology nephroblastomas in this series is
an interesting and important observation.
Could a subset of nephroblastomas merit a trial of
selective tyrosine receptor kinase inhibition and be suscep-
tible to this therapeutic approach? As the presence of either
KIT or PDGFRα mutations is predictive of tumour
response to selective receptor tyrosine kinase inhibition
with imatinib in gastrointestinal stromal tumours [2, 18,
20], though to a lesser degree for PDGFRα mutations and
no KIT mutations were detected in the subset of nephro-
blastomas investigated in this study, we therefore proceeded
to determine also PDGFRα sequences in those nephro-
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blastomas with KIT expression, and in the absence of an
immunohistochemical screening test for PDGFRα, also in
those tumours without KIT expression. Moreover, we
investigated EGFR-expressing nephroblastomas for EGFR
sequence alterations. None of the 63 nephroblastomas
investigated showed any sequence alteration in any receptor
tyrosine kinase analysed. Our present study of mutation
analysis of 63 and 209 nephroblastomas, respectively,
suggests that neither KIT, EGFR nor PDGFRα mutations
appear to play a significant role in tumour pathogenesis.
KIT and EGFR expression therefore do not appear to result
from constitutionally activating mutations in the investigated
exons in these nephroblastomas. Why do these tumours
express KIT and/or EGFR in the absence of respective gene
mutations? Importantly, KIT and PDGFRα receptor tyrosine
kinases may be activated by mechanisms other than gene
mutation, such as gene fusion and amplification, autocrine
and paracrine stimulation of the receptor by its ligand, loss
of phosphatase activity, cross-activation by other kinases
and epigenetic promoter activation via methylation status
alteration. Therefore, absence of KIT or PDGFRα muta-
tions does not exclude selective tyrosine kinase inhibition
with imatinib as targeted therapeutic strategy in the KIT-
expressing nephroblastomas [35]. Importantly, imatinib has
been shown to also effectively inhibit wild-type KIT and
PDGFR receptors [2]. Similarly, in a previous study
correlating KIT immuno-phenotype with response to tyro-
sine kinase inhibitor, imatinib even showed a response in
gastrointestinal stromal tumours with only weak immuno-
histochemical staining [4]. Of note, in non-small-cell lung
cancer, EGFR receptor tyrosine kinase inhibition with
erlotinib/Tarceva® has recently been found to be effective
in non-small-cell lung cancer with wild-type EGFR [5].
Therefore, as numbers in this current study are small, further
investigations are required to evaluate a potential benefit,
and future clinical therapeutic studies might be considered
for the limited poor prognostic subgroup of nephroblastomas
with high-risk histology also in the absence of KIT,
PDGFRα or EGFR mutations. Nevertheless, at present, the
question remains open whether the small group of poor
prognostic nephroblastomas will benefit from additional
receptor tyrosine kinase inhibition.
Addressing the question of preoperative chemotherapy
and evaluation of the patient outcome in relation to
expression of KIT and EGFR, comparing with patients
without preoperative chemotherapy, such a comparison is
likely to be biased for the following reasons. According to
the current SIOP protocol, most nephroblastoma patients
are treated by preoperative chemotherapy [15]. Only a
minority of very young patients are judged not to require
chemotherapy because of a high likelihood of congenital
mesoblastic nephroma. Therefore, the criteria of patient
inclusion will render the preoperatively treated versus the
preoperatively untreated nephroblastoma groups incongruent.
It has been argued that preoperative chemotherapy may
unpredictably alter tumour protein expression and genetics;
therefore, only analysis of untreated tumour tissue should
be regarded as reliable. However, it is now being recog-
nised that surviving blastemal tumour tissue after chemo-
therapy constitutes an indicator towards poor chemotherapy
response and prognosis, and therefore, nephroblastomas of
post-chemotherapy blastemal predominant histology are
currently classified among the high-risk histology group
accordingly, in contrast to those blastemal predominant
nephroblastomas without preoperative chemotherapy. Anal-
ysis of a study population of nephroblastomas with available
pre-chemotherapy pre-surgical biopsy as well as post-
chemotherapy specimens of identical tumours should be
undertaken in the future to further contribute to resolve this
issue.
In summary, a minor proportion of nephroblastomas
express KIT and EGFR. However, KIT, PDGFRα and
EGFR mutations do not appear to significantly contribute to
nephroblastoma pathogenesis. Hence, unlike in gastrointes-
tinal stromal tumours, leukemia and non-small-cell lung
cancer, there appears to be no comparable molecular basis
for potential selective tyrosine kinase inhibition in nephro-
blastoma. In nephroblastomas, immunohistochemical KIT
and EGFR expression does not appear to bear a direct
association with outcome. Nevertheless, as numbers of
high-risk histology nephroblastomas are small, further
clinical evaluation studies might be considered to elucidate
a potential therapeutic benefit for this poor prognostic
subgroup of patients.
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